{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T00:16:05Z","timestamp":1767485765108,"version":"3.48.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Jinling Hospital of Nanjing","award":["YYMS 2021037"],"award-info":[{"award-number":["YYMS 2021037"]}]},{"name":"Jinling Hospital of Nanjing","award":["YYMS 2021037"],"award-info":[{"award-number":["YYMS 2021037"]}]},{"name":"Jinling Hospital of Nanjing","award":["YYMS 2021037"],"award-info":[{"award-number":["YYMS 2021037"]}]},{"name":"Jinling Hospital of Nanjing","award":["YYMS 2021037"],"award-info":[{"award-number":["YYMS 2021037"]}]},{"name":"Jinling Hospital of Nanjing","award":["YYMS 2021037"],"award-info":[{"award-number":["YYMS 2021037"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-025-06712-4","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T02:25:05Z","timestamp":1764210305000},"page":"6215-6228","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The impact of CD81 on immune cells and clinical prognosis in multiple myeloma"],"prefix":"10.1007","volume":"104","author":[{"given":"Qian","family":"Zhao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengyao","family":"LV","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanfei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0661-3305","authenticated-orcid":false,"given":"Feng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,27]]},"reference":[{"issue":"2","key":"6712_CR1","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1080\/10428194.2020.1827253","volume":"62","author":"M Braunlin","year":"2021","unstructured":"Braunlin M, Belani R, Buchanan J, Wheeling T, Kim C (2021) Trends in the multiple myeloma treatment landscape and survival: a U.S. analysis using 2011\u20132019 oncology clinic electronic health record data. Leuk Lymphoma 62(2):377\u2013386. https:\/\/doi.org\/10.1080\/10428194.2020.1827253","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"6712_CR2","doi-asserted-by":"publisher","first-page":"2887","DOI":"10.1038\/s41375-020-0921-y","volume":"34","author":"CJ Neuse","year":"2020","unstructured":"Neuse CJ, Lomas OC, Schliemann C, Shen YJ, Manier S, Bustoros M, Ghobrial IM (2020) Genome instability in multiple myeloma. Leukemia 34(11):2887\u20132897. https:\/\/doi.org\/10.1038\/s41375-020-0921-y","journal-title":"Leukemia"},{"issue":"1","key":"6712_CR3","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s10238-023-01277-w","volume":"24","author":"Q Zhao","year":"2024","unstructured":"Zhao Q, Li F, Li J, Xia Y, Wang J, Chen L (2024) An inflammatory response-related gene signature can predict the prognosis and impact the immune infiltration of multiple myeloma. Clin Exp Med 24(1):16. https:\/\/doi.org\/10.1007\/s10238-023-01277-w","journal-title":"Clin Exp Med"},{"issue":"7","key":"6712_CR4","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1084\/jem.20190733","volume":"216","author":"R K\u00fcppers","year":"2019","unstructured":"K\u00fcppers R (2019) CD81 as target for B cell lymphomas. J Exp Med 216(7):1469\u20131470. https:\/\/doi.org\/10.1084\/jem.20190733","journal-title":"J Exp Med"},{"issue":"7","key":"6712_CR5","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.3390\/cancers15072186","volume":"15","author":"C Bailly","year":"2023","unstructured":"Bailly C, Thuru X (2023) Targeting of tetraspanin CD81 with monoclonal antibodies and small molecules to combat cancers and viral diseases. Cancers (Basel) 15(7):2186. https:\/\/doi.org\/10.3390\/cancers15072186","journal-title":"Cancers (Basel)"},{"issue":"4","key":"6712_CR6","doi-asserted-by":"publisher","first-page":"e0125405","DOI":"10.1371\/journal.pone.0125405","volume":"10","author":"MS Lee","year":"2015","unstructured":"Lee MS, Kim JH, Lee JS, Yun SJ, Kim WJ, Ahn H, Park J (2015) Prognostic significance of CREB-binding protein and CD81 expression in primary high grade non-muscle invasive bladder cancer: identification of novel biomarkers for bladder cancer using antibody microarray. PLoS ONE 10(4):e0125405. https:\/\/doi.org\/10.1371\/journal.pone.0125405","journal-title":"PLoS ONE"},{"issue":"22","key":"6712_CR7","doi-asserted-by":"publisher","first-page":"15691","DOI":"10.1074\/jbc.M113.534206","volume":"289","author":"IK Hong","year":"2014","unstructured":"Hong IK, Byun HJ, Lee J, Jin YJ, Wang SJ, Jeoung DI, Kim YM, Lee H (2014) The tetraspanin CD81 protein increases melanoma cell motility by up-regulating metalloproteinase MT1-MMP expression through the pro-oncogenic Akt-dependent Sp1 activation signaling pathways. J Biol Chem 289(22):15691\u201315704. https:\/\/doi.org\/10.1074\/jbc.M113.534206","journal-title":"J Biol Chem"},{"issue":"6","key":"6712_CR8","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1007\/s13402-019-00472-w","volume":"42","author":"N Mizoshiri","year":"2019","unstructured":"Mizoshiri N, Shirai T, Terauchi R, Tsuchida S, Mori Y, Hayashi D, Kishida T, Arai Y, Mazda O, Nakanishi T et al (2019) The tetraspanin CD81 mediates the growth and metastases of human osteosarcoma. Cell Oncol (Dordr) 42(6):861\u2013871. https:\/\/doi.org\/10.1007\/s13402-019-00472-w","journal-title":"Cell Oncol (Dordr)"},{"issue":"9","key":"6712_CR9","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1074\/mcp.RA119.001446","volume":"18","author":"ZC Uretmen Kagiali","year":"2019","unstructured":"Uretmen Kagiali ZC, Sanal E, Karayel \u00d6, Polat AN, Saatci \u00d6, Ersan PG, Trappe K, Renard BY, \u00d6nder TT, Tuncbag N et al (2019) Systems-level analysis reveals multiple modulators of epithelial-mesenchymal transition and identifies DNAJB4 and CD81 as novel metastasis inducers in breast cancer. Mol Cell Proteomics 18(9):1756\u20131771. https:\/\/doi.org\/10.1074\/mcp.RA119.001446","journal-title":"Mol Cell Proteomics"},{"issue":"2","key":"6712_CR10","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.humpath.2009.07.022","volume":"41","author":"RF Luo","year":"2010","unstructured":"Luo RF, Zhao S, Tibshirani R, Myklebust JH, Sanyal M, Fernandez R, Gratzinger D, Marinelli RJ, Lu ZS, Wong A et al (2010) CD81 protein is expressed at high levels in normal germinal center B cells and in subtypes of human lymphomas. Hum Pathol 41(2):271\u2013280. https:\/\/doi.org\/10.1016\/j.humpath.2009.07.022","journal-title":"Hum Pathol"},{"issue":"3","key":"6712_CR11","doi-asserted-by":"publisher","first-page":"e159924","DOI":"10.1172\/jci.insight.159924","volume":"8","author":"J Jakubikova","year":"2023","unstructured":"Jakubikova J, Cholujova D, Beke G, Hideshima T, Klucar L, Leiba M, Jamroziak K, Richardson PG, Kastritis E, Dorfman DM et al (2023) Heterogeneity of B cell lymphopoiesis in patients with premalignant and active myeloma. JCI Insight 8(3):e159924. https:\/\/doi.org\/10.1172\/jci.insight.159924","journal-title":"JCI Insight"},{"issue":"8","key":"6712_CR12","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1038\/leu.2012.42","volume":"26","author":"B Paiva","year":"2012","unstructured":"Paiva B, Guti\u00e9rrez NC, Chen X, V\u00eddriales MB, Montalb\u00e1n M, Rosi\u00f1ol L, Oriol A, Mart\u00ednez-L\u00f3pez J, Mateos MV, L\u00f3pez-Corral L et al (2012) Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients. Leukemia 26(8):1862\u20131869. https:\/\/doi.org\/10.1038\/leu.2012.42","journal-title":"Leukemia"},{"issue":"4","key":"6712_CR13","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1007\/s00277-023-05573-z","volume":"103","author":"L Shi","year":"2024","unstructured":"Shi L, Yan W, Xu J, Li L, Cui J, Liu Y, Du C, Yu T, Zhang S, Sui W et al (2024) Immunophenotypic profile defines cytogenetic stability and unveils distinct prognoses in patients with newly-diagnosed multiple myeloma (NDMM). Ann Hematol 103(4):1305\u20131315. https:\/\/doi.org\/10.1007\/s00277-023-05573-z","journal-title":"Ann Hematol"},{"issue":"2","key":"6712_CR14","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/leu.2016.211","volume":"31","author":"B Paiva","year":"2017","unstructured":"Paiva B, Puig N, Cedena MT, de Jong BG, Ruiz Y, Rapado I, Martinez-Lopez J, Cordon L, Alignani D, Delgado JA et al (2017) Differentiation stage of myeloma plasma cells: biological and clinical significance. Leukemia 31(2):382\u2013392. https:\/\/doi.org\/10.1038\/leu.2016.211","journal-title":"Leukemia"},{"issue":"4","key":"6712_CR15","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1038\/leu.2017.320","volume":"32","author":"P Arana","year":"2018","unstructured":"Arana P, Paiva B, Cedena MT, Puig N, Cordon L, Vidriales MB, Gutierrez NC, Chiodi F, Burgos L, Anglada LL et al (2018) Prognostic value of antigen expression in multiple myeloma: a PETHEMA\/GEM study on 1265 patients enrolled in four consecutive clinical trials. Leukemia 32(4):971\u2013978. https:\/\/doi.org\/10.1038\/leu.2017.320","journal-title":"Leukemia"},{"issue":"12","key":"6712_CR16","doi-asserted-by":"publisher","first-page":"5920","DOI":"10.1002\/cam4.1840","volume":"7","author":"F Chen","year":"2018","unstructured":"Chen F, Hu Y, Wang X, Fu S, Liu Z, Zhang J (2018) Expression of CD81 and CD117 in plasma cell myeloma and the relationship to prognosis. Cancer Med 7(12):5920\u20135927. https:\/\/doi.org\/10.1002\/cam4.1840","journal-title":"Cancer Med"},{"issue":"4","key":"6712_CR17","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1182\/bloodadvances.2022008021","volume":"7","author":"CV Edwards","year":"2023","unstructured":"Edwards CV, Hassan H, Yildirim C, Ferri G, Verma KP, Murray Horwitz ME, Fillmore NR, Munshi NC (2023) Peripheral blood monocyte count is a dynamic prognostic biomarker in multiple myeloma. Blood Adv 7(4):482\u2013490. https:\/\/doi.org\/10.1182\/bloodadvances.2022008021","journal-title":"Blood Adv"},{"issue":"7","key":"6712_CR18","doi-asserted-by":"publisher","first-page":"6111","DOI":"10.3390\/curroncol30070455","volume":"30","author":"E Cencini","year":"2023","unstructured":"Cencini E, Sicuranza A, Ciofini S, Fabbri A, Bocchia M, Gozzetti A (2023) Tumor-associated macrophages in multiple myeloma: key role in disease biology and potential therapeutic implications. Curr Oncol 30(7):6111\u20136133. https:\/\/doi.org\/10.3390\/curroncol30070455","journal-title":"Curr Oncol"},{"issue":"68","key":"6712_CR19","doi-asserted-by":"publisher","first-page":"112685","DOI":"10.18632\/oncotarget.22340","volume":"8","author":"X Chen","year":"2017","unstructured":"Chen X, Chen J, Zhang W, Sun R, Liu T, Zheng Y, Wu Y (2017) Prognostic value of diametrically polarized tumor-associated macrophages in multiple myeloma. Oncotarget 8(68):112685\u2013112696. https:\/\/doi.org\/10.18632\/oncotarget.22340","journal-title":"Oncotarget"},{"issue":"14","key":"6712_CR20","doi-asserted-by":"publisher","first-page":"3239","DOI":"10.7150\/jca.30102","volume":"10","author":"H Wang","year":"2019","unstructured":"Wang H, Hu WM, Xia ZJ, Liang Y, Lu Y, Lin SX, Tang H (2019) High numbers of CD163\u2009+\u2009tumor-associated macrophages correlate with poor prognosis in multiple myeloma patients receiving bortezomib-based regimens. J Cancer 10(14):3239\u20133245. https:\/\/doi.org\/10.7150\/jca.30102","journal-title":"J Cancer"},{"issue":"9","key":"6712_CR21","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.leukres.2015.06.003","volume":"39","author":"MN Andersen","year":"2015","unstructured":"Andersen MN, Andersen NF, R\u00f8dgaard-Hansen S, Hokland M, Abildgaard N, M\u00f8ller HJ (2015) The novel biomarker of alternative macrophage activation, soluble mannose receptor (sMR\/sCD206): implications in multiple myeloma. Leuk Res 39(9):971\u2013975. https:\/\/doi.org\/10.1016\/j.leukres.2015.06.003","journal-title":"Leuk Res"},{"issue":"8","key":"6712_CR22","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/s1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, Munshi N, Lonial S, Blad\u00e9 J, Mateos MV et al (2016) International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 17(8):e328\u2013e346. https:\/\/doi.org\/10.1016\/s1470-2045(16)30206-6","journal-title":"Lancet Oncol"},{"issue":"S1","key":"6712_CR23","first-page":"265","volume":"138","author":"DM Francesco","year":"2021","unstructured":"Francesco DM, Christina Y, Annamaria C, Aljoufi A, Silvia M, David RG, Bh E, Fabiana P (2021) Mapping the high-risk multiple myeloma cell surface proteome identifies T-cell inhibitory receptors for immune targeting. Blood 138(S1):265\u2013265","journal-title":"Blood"},{"issue":"3","key":"6712_CR24","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41408-021-00440-4","volume":"11","author":"A Visram","year":"2021","unstructured":"Visram A, Dasari S, Anderson E, Kumar S, Kourelis TV (2021) Relapsed multiple myeloma demonstrates distinct patterns of immune microenvironment and malignant cell-mediated immunosuppression. Blood Cancer J 11(3):45. https:\/\/doi.org\/10.1038\/s41408-021-00440-4","journal-title":"Blood Cancer J"},{"issue":"7","key":"6712_CR25","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.3390\/jcm11071809","volume":"11","author":"E Lebel","year":"2022","unstructured":"Lebel E, Nachmias B, Pick M, Gross Even-Zohar N, Gatt ME (2022) Understanding the bioactivity and prognostic implication of commonly used surface antigens in multiple myeloma. J Clin Med 11(7):1809. https:\/\/doi.org\/10.3390\/jcm11071809","journal-title":"J Clin Med"},{"issue":"1","key":"6712_CR26","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s12943-022-01648-z","volume":"21","author":"Y Liang","year":"2022","unstructured":"Liang Y, He H, Wang W, Wang H, Mo S, Fu R, Liu X, Song Q, Xia Z, Wang L (2022) Malignant clonal evolution drives multiple myeloma cellular ecological diversity and microenvironment reprogramming. Mol Cancer 21(1):182. https:\/\/doi.org\/10.1186\/s12943-022-01648-z","journal-title":"Mol Cancer"},{"key":"6712_CR27","doi-asserted-by":"publisher","first-page":"801882","DOI":"10.3389\/fnmol.2021.801882","volume":"14","author":"A Becic","year":"2021","unstructured":"Becic A, Leifeld J, Shaukat J, Hollmann M (2021) Tetraspanins as potential modulators of glutamatergic synaptic function. Front Mol Neurosci 14:801882. https:\/\/doi.org\/10.3389\/fnmol.2021.801882","journal-title":"Front Mol Neurosci"},{"issue":"38","key":"6712_CR28","doi-asserted-by":"publisher","first-page":"62377","DOI":"10.18632\/oncotarget.11481","volume":"7","author":"T Boyer","year":"2016","unstructured":"Boyer T, Guihard S, Roumier C, Peyrouze P, Gonzales F, Berthon C, Quesnel B, Preudhomme C, Behal H, Duhamel A et al (2016) Tetraspanin CD81 is an adverse prognostic marker in acute myeloid leukemia. Oncotarget 7(38):62377\u201362385. https:\/\/doi.org\/10.18632\/oncotarget.11481","journal-title":"Oncotarget"},{"issue":"18","key":"6712_CR29","doi-asserted-by":"publisher","first-page":"4393","DOI":"10.1182\/bloodadvances.2020001592","volume":"4","author":"A Quagliano","year":"2020","unstructured":"Quagliano A, Gopalakrishnapillai A, Kolb EA, Barwe SP (2020) CD81 knockout promotes chemosensitivity and disrupts in vivo homing and engraftment in acute lymphoblastic leukemia. Blood Adv 4(18):4393\u20134405. https:\/\/doi.org\/10.1182\/bloodadvances.2020001592","journal-title":"Blood Adv"},{"key":"6712_CR30","doi-asserted-by":"publisher","first-page":"216043","DOI":"10.1016\/j.canlet.2022.216043","volume":"559","author":"Q Wang","year":"2023","unstructured":"Wang Q, Qin Y, Li B (2023) CD8(+) T cell exhaustion and cancer immunotherapy. Cancer Lett 559:216043. https:\/\/doi.org\/10.1016\/j.canlet.2022.216043","journal-title":"Cancer Lett"},{"issue":"9","key":"6712_CR31","doi-asserted-by":"publisher","first-page":"806","DOI":"10.2174\/1568009617666170214102301","volume":"17","author":"Y Kawano","year":"2017","unstructured":"Kawano Y, Roccaro AM, Ghobrial IM, Azzi J (2017) Multiple myeloma and the immune microenvironment. Curr Cancer Drug Targets 17(9):806\u2013818. https:\/\/doi.org\/10.2174\/1568009617666170214102301","journal-title":"Curr Cancer Drug Targets"},{"issue":"4","key":"6712_CR32","doi-asserted-by":"publisher","first-page":"625","DOI":"10.3390\/cancers13040625","volume":"13","author":"R Lopes","year":"2021","unstructured":"Lopes R, Caetano J, Ferreira B, Barahona F, Carneiro EA, Jo\u00e3o C (2021) The immune microenvironment in multiple myeloma: friend or foe? Cancers (Basel) 13(4):625. https:\/\/doi.org\/10.3390\/cancers13040625","journal-title":"Cancers (Basel)"},{"issue":"1","key":"6712_CR33","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41525-022-00340-x","volume":"8","author":"W Pilcher","year":"2023","unstructured":"Pilcher W, Thomas BE, Bhasin SS, Jayasinghe RG, Yao L, Gonzalez-Kozlova E, Dasari S, Kim-Schulze S, Rahman A, Patton J et al (2023) Cross center single-cell RNA sequencing study of the immune microenvironment in rapid progressing multiple myeloma. NPJ Genom Med 8(1):3. https:\/\/doi.org\/10.1038\/s41525-022-00340-x","journal-title":"NPJ Genom Med"},{"issue":"4","key":"6712_CR34","doi-asserted-by":"publisher","first-page":"e003975","DOI":"10.1136\/jitc-2021-003975","volume":"10","author":"J Sun","year":"2022","unstructured":"Sun J, Park C, Guenthner N, Gurley S, Zhang L, Lubben B, Adebayo O, Bash H, Chen Y, Maksimos M et al (2022) Tumor-associated macrophages in multiple myeloma: advances in biology and therapy. J Immunother Cancer 10(4):e003975. https:\/\/doi.org\/10.1136\/jitc-2021-003975","journal-title":"J Immunother Cancer"},{"issue":"1","key":"6712_CR35","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s13045-022-01366-5","volume":"15","author":"K Beider","year":"2022","unstructured":"Beider K, Voevoda-Dimenshtein V, Zoabi A, Rosenberg E, Magen H, Ostrovsky O, Shimoni A, Weiss L, Abraham M, Peled A et al (2022) CXCL13 chemokine is a novel player in multiple myeloma osteolytic microenvironment, M2 macrophage polarization, and tumor progression. J Hematol Oncol 15(1):144. https:\/\/doi.org\/10.1186\/s13045-022-01366-5","journal-title":"J Hematol Oncol"},{"issue":"24","key":"6712_CR36","doi-asserted-by":"publisher","first-page":"4838","DOI":"10.1002\/cam4.4814","volume":"11","author":"J Zhang","year":"2022","unstructured":"Zhang J, Liu Z, Cao P, Wang H, Liu H, Hua L, Xue H, Fu R (2022) Tumor-associated macrophages regulate the function of cytotoxic T lymphocyte through PD-1\/PD-L1 pathway in multiple myeloma. Cancer Med 11(24):4838\u20134848. https:\/\/doi.org\/10.1002\/cam4.4814","journal-title":"Cancer Med"},{"issue":"4","key":"6712_CR37","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1038\/leu.2015.191","volume":"30","author":"S Panchabhai","year":"2016","unstructured":"Panchabhai S, Kelemen K, Ahmann G, Sebastian S, Mantei J, Fonseca R (2016) Tumor-associated macrophages and extracellular matrix metalloproteinase inducer in prognosis of multiple myeloma. Leukemia 30(4):951\u2013954. https:\/\/doi.org\/10.1038\/leu.2015.191","journal-title":"Leukemia"},{"issue":"1","key":"6712_CR38","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/ejh.12296","volume":"93","author":"MN Andersen","year":"2014","unstructured":"Andersen MN, Abildgaard N, Maniecki MB, M\u00f8ller HJ, Andersen NF (2014) Monocyte\/macrophage-derived soluble CD163: a novel biomarker in multiple myeloma. Eur J Haematol 93(1):41\u201347. https:\/\/doi.org\/10.1111\/ejh.12296","journal-title":"Eur J Haematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06712-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06712-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06712-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T00:15:09Z","timestamp":1767485709000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06712-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,27]]},"references-count":38,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6712"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06712-4","relation":{},"ISSN":["1432-0584"],"issn-type":[{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2025,11,27]]},"assertion":[{"value":"24 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study did not involve any ethical issues as we did not study any human or animal subjects, nor did we collect any personal information or sensitive data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}